Search

CN-121991170-A - Preparation method of probiotics and application of probiotics in prevention and treatment of helicobacter pylori

CN121991170ACN 121991170 ACN121991170 ACN 121991170ACN-121991170-A

Abstract

The invention provides a preparation method of probiotics and application of probiotics in prevention and treatment of helicobacter pylori. Furthermore, the probiotic composition for treating helicobacter pylori consists of broad-spectrum antibacterial peptide, pediococcus pentosaceus CCTCC NO: M2024601 and Lactobacillus plantarum CCTCC M2017459, and the probiotic combined antibacterial peptide is prepared into the composition which has stronger effect of inhibiting helicobacter pylori in a broad spectrum than that of single use, and has good application prospect in animal experiments.

Inventors

  • Request for anonymity

Assignees

  • 北京辉靳生物科技有限公司

Dates

Publication Date
20260508
Application Date
20260303

Claims (8)

  1. 1. A broad-spectrum antibacterial peptide for treating helicobacter pylori is disclosed, which is characterized in that the amino acid sequence is shown as SEQ ID NO. 4.
  2. 2. A kit for treating helicobacter pylori, which is characterized by comprising the broad-spectrum antibacterial peptide as defined in claim 1, and Pediococcus pentosaceus CCTCC NO: M2024601 and Lactobacillus plantarum CCTCC M2017459.
  3. 3. The kit of claim 2, wherein the pediococcus pentosaceus CCTCC NO: M2024601 and the lactobacillus plantarum CCTCC M2017459 are combined according to a weight ratio of 1:1.
  4. 4. Use of pediococcus pentosaceus cctccc NO: M2024601 and lactobacillus plantarum cctccc M2017459 in combination with the broad-spectrum antimicrobial peptide of claim 1, wherein the antimicrobial peptide is used 2h apart from pediococcus pentosaceus cccc NO: M2024601 and lactobacillus plantarum cctccc M2017459, for the preparation of a kit for the treatment of helicobacter pylori.
  5. 5. The use as claimed in claim 4, wherein the Pediococcus pentosaceus CCTCC NO: M2024601 and Lactobacillus plantarum CCTCC M2017459 are used in combination in a weight ratio of 1:1.
  6. 6. The use according to claim 4 or 5, wherein the composition further comprises a pharmaceutically acceptable carrier.
  7. 7. The use according to claim 4 or 5, wherein the probiotic is in the form of a lyophilisate.
  8. 8. Use of a broad-spectrum antibacterial peptide against helicobacter pylori according to claim 1 for the preparation of a medicament for the treatment of helicobacter pylori.

Description

Preparation method of probiotics and application of probiotics in prevention and treatment of helicobacter pylori Technical Field The application relates to the field of biology, in particular to a preparation method of probiotics and application of probiotics in prevention and treatment of helicobacter pylori. Background Helicobacter pylori has been identified as the leading cause of chronic gastritis, peptic ulcer, and as a class I oncogene that induces gastric cancer since the discovery of helicobacter pylori in the 80 s of the 20 th century. At present, a triple therapy consisting of a Proton Pump Inhibitor (PPI) or a bismuth agent and two antibiotics is a recognized standard scheme for eradicating H.pyri, and the antibiotics can be amoxicillin, clarithromycin or nitroimidazole, but the eradication effect is not ideal due to the large adverse reaction of medicines and poor compliance and the drug resistance problem of clarithromycin, metronidazole and the like. H. Resistance of pyri to antibiotics is a major factor in eradication failure. The drug resistance rate of the metronidazole is continuously increased from less than 20% at the beginning of the 90 s to 50% -70% of clarithromycin at the end of the 90 s, and mixed drug resistance exists between the metronidazole and the clarithromycin. A large number of researches show that the combination and large amount of antibiotics can cause the imbalance of normal flora in intestinal tracts, so that the anti-colonization capability of the intestinal tracts to pathogenic bacteria is weakened, various passerby bacteria and drug-resistant strains form dominant flora to colonize the intestinal tracts for mass propagation, the increase of pathogenic strains can cause the further reduction of the intestinal colonization bacteria again, and the application of proton pump inhibitors can cause the increase of pH in the stomach, which is also one of the causes of mass propagation of the passerby bacteria. The intestinal microecological environment is changed badly, a series of digestive tract symptoms such as abdominal distension, anorexia, diarrhea and constipation are caused, serious adverse reactions such as antibiotic-associated enteritis and even pseudomembranous enteritis are caused, and after H.pyri infection patients are treated by combining acid inhibitors and antibiotics in Europe, america, japan and other countries, clostridium difficile diarrhea (CDAD) is paid attention to. Recently, many researchers have proposed new methods for resisting H.pyri infection, and the unique advantages of traditional Chinese medicine in treating helicobacter pylori-related gastropathy and eradicating helicobacter pylori are paid attention to by students, and traditional Chinese medicine is used more and more frequently in treatment or auxiliary treatment, but the traditional Chinese medicine still has certain side effects, and the leaching amount of the traditional Chinese medicine in the body is less due to the existence of plant cell walls, so that the effective ingredients entering the body are greatly reduced. Along with the development of technology, researches show that probiotics can generate a plurality of extracellular enzymes in the metabolic process, and the extracellular enzymes can degrade components such as cellulose and the like, so that the structure of plant cell walls is damaged, and the curative effect of the traditional Chinese medicine is indirectly improved. Besides, the traditional Chinese medicine can reduce the toxic and side effects of the traditional Chinese medicine through probiotic fermentation. However, the traditional Chinese medicine has slow effect and poor curative effect, and is still an important direction of research. With advances in technology, non-antibiotic formulations, including probiotics, antioxidants, etc., have been included to alter or complement existing antimicrobial treatment regimens, where probiotics are particularly advantageous in improving h. Treatment of H.pyri infection with Lactobacillus acidophilus LB (LB) or symbiotic yeast probiotic added with inulin (SbI) 254 asymptomatic children were selected in san Diego city and H.pyri positive children were randomized into 3 groups each treated by the antibiotics (lansoprazole, clarithromycin and amoxicillin) 8 d, daily SbI, 8 wk continuously, and daily LB, 8 wk at a rate of 66%, 12% and 6.5% respectively after the treatment of 3 groups of H.pyri infection, the 13 C-baseline difference was moderate, But has significant change, but the infant taking LB does not have the change, and the result shows that the yeast probiotics can interfere the proliferation process of H. The field of clinical experimental study, 59 H.pyri positive patients were treated with Lactobacillus acidophilus La5 and Bifidobacterium Bb12 or AB-Yogurt after meals, 11 H.pyri positive patients were treated with milk as placebo group, and H.pyri infection was determined by 13 C-urea exhalation test bef